| Apolipoprotein analogues -> Monitor Keywords |
|
|
 
Apolipoprotein analoguesApolipoprotein analogues description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20090136467, Apolipoprotein analogues. Brief Patent Description - Full Patent Description - Patent Application Claims
The invention relates to a pharmaceutical composition comprising an apolipoprotein construct, to an apolipoprotein construct, a nucleic acid sequence encoding the apolipoprotein construct, a vector comprising the nucleic acid sequence, a method for producing the apolipoprotein construct, and a method of treatment comprising administering the apolipoprotein construct. In the following, the term Apo A or apolipoprotein A will be used to designate any of the three apolipoproteins, Apolipoprotein A I, Apolipoprotein A II, or Apolipoprotein A IV. Cardiovascular diseases caused by atherosclerosis in the vessels is the most frequent cause of death in the industrialised countries of the World. One of the pathogenic factors causing atherosclerosis is the deposition of cholesterol in the vessel walls leading to plaque formation and eventually to arterosclerosis and increased risk of infarction. Apolipoprotein A-1 (apo-A-1) is the main component of plasma HDL (high density lipoprotein), which is negatively correlated to the presence of arterosclerosis. There is strong experimental evidence that this effect is caused by so-called reverse cholesterol transport from peripheral tissues to the liver. There is also experimental evidence that this reverse cholesterol transport can be stimulated in mammals by injection of apo-A-1. Apolipoprotein A-1 is rapidly cleared from plasma. It is believed that Apo-A-1 is to a large extent removed from plasma by filtration in the kidneys without being broken down first (Braschi et al 1999, J Lipid Res, 40:522-532; Braschi et al 2000, Biochemistry, 39:5441-5449; Glass et al 1983, J Biol Chem 258:7161-7167). The short plasma half-life of apolipoprotein A is a constraint against using the protein in the treatment of atherosclerosis. U.S. Pat. No. 5,876,968 (SIRTORI ET AL.) concerns substantially pure dimers of a variant of apo-A-1 called apolipoprotein A-1-Milano. Medicaments containing the dimer can be used for preventing thrombosis or they can be used as a prodrug for the monomer. A specific feature of this particular variant of apo-A-I is its ability to form covalent dimers with itself. The authors speculated that the presence of Apo A-I-M may be responsible for a prolonged plasma half-life, but no conclusive data have been presented. U.S. Pat. No. 5,643,757 (SHA-IL ET AL.) discloses a method for the production of pure, stable, mature and biologically active human apolipoprotein A-I in high yield. U.S. Pat. No. 5,990,081 (AGELAND ET AL.) discloses a method for treatment of arterosclerosis or cardiovascular diseases by administering a therapeutically effective amount of apoliproprotein A or apolipoprotein E. WO 96/37608 (RHONE-POULENC ROHRER ET AL.) describes human homologous dimers of apolipoprotein A-I variants comprising cystein in position 151. The presence of the cystein residue in the amino acid sequence allows the formation of dimers via disulphide bridges between the monomers. The reference furthermore discloses the corresponding nucleic acid sequences and vectors comprising these as well as pharmaceutical compositions comprising the variants and the use of these in gene therapy. WO 90/12879 (Sirtori et al) and WO 94/13819 (Kabi Pharmacia) disclose methods for preparation of ApoA-I and ApoA-IM in yeast and E. coli respectively. The documents also disclose the use of ApoA-I and ApoA-IM as a medicament for the treatment of atherosclerosis and cardiovascular diseases. In conclusion the prior art is mainly concerned with the use of native ApoA-I or ApoA-IM monomer or ApoA-IM dimer as medicaments for the treatment of vascular diseases, despite the known disadvantages of these proteins (mainly rapid clearance). The prior art does not suggest to modify ApoA-I in order to obtain constructs with increased ability to perform reverse cholesterol transport and/or with longer plasma half life. It is thus one object of the present invention to provide such ApoA constructs, which may be used for treatment and/or prevention of cardiovascular diseases. In a first aspect the invention relates to a pharmaceutical composition comprising an apolipoprotein construct having the general formula
Continue reading about Apolipoprotein analogues... Full patent description for Apolipoprotein analogues Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Apolipoprotein analogues patent application. Patent Applications in related categories: 20090291068 - Modulation of bio-electrical rhythms via a novel engineering approach - The present invention relates to novel compositions and methods to induce, and/or modulate bio-electrical rhythms (e.g. in cardiac, neuronal and pancreatic cells) by fine-tuning the activity of HCN-encoded pacemaker channels via a novel protein- and genetic-engineering approach to augment or attenuate the associated physiological responses (e.g. heart beat, neuronal firing, ... ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Apolipoprotein analogues or other areas of interest. ### Previous Patent Application: Targeting of herpes simplex virus to specific receptors Next Patent Application: Methods and compositions for cell therapy Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Apolipoprotein analogues patent info. IP-related news and info Results in 3.9861 seconds Other interesting Feshpatents.com categories: Electronics: Semiconductor , Audio , Illumination , Connectors , Crypto , paws |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
